Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients With Moderate to Severe Glabellar Lines

NCT03216408 is registered in ClinicalTrials.gov with Medy-Tox as lead sponsor.

NCT NCT03216408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03216408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients With Moderate to Severe Glabellar Lines
Lead sponsor
Medy-Tox
Phase
Phase 3
Overall status
Completed
Start date
March 30, 2016
Completion date
March 7, 2017
Enrollment
504 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines